Motilent, a company that specializes in assessing digestive diseases through the analysis of AI medical images, has raised £ 1.2 million from the National Institute for Health Research and Care.
NIHR funding will enable him to develop and implement his technology in more than 10 UK hospitals, including UCLH, Nottingham University Hospital and Fremley Park Hospital.
Crohn’s disease is a painful, debilitating inflammatory bowel condition that affects 115,000 people in the UK, with 33% diagnosed before the age of 21. Currently, anti-inflammatory drugs are the standard of care.
However, for 40% who do not experience inflammatory symptoms, these drugs are ineffective and can cause serious side effects, and cost the UK economy more than £ 280 million annually.
Currently, 69% of the UK population is experiencing persistent bowel problems, leading to 1 in 8 deaths in the UK. As a result, innovation in caring for those affected by these conditions is a critical focus for the NIHR.
Through its Invention for Innovation (i4i) program, NIHR has invested £ 14 million in the Oral and Gastrointestinal (GI) study – supporting the development of medical technology, helping them jump from concept to clinic and improve patient care and recovery.
Building on its initial investment of £ 685,000, the NIHR has awarded Motilent an additional £ 562,000 to support the deployment of GIQuant in NHS trusts across the UK. The investment is the latest NIHR research grant awarded by Motilent – previous awards have focused on accelerating the development of GIQuant by assessing Crohn’s disease activity using MRI and predicting treatment response in patients with Crohn’s disease.
Motilent’s post-processing software and CE-marked post-processing software, GIQuant, is already used by several UK health services, including Great Ormond Street Hospital, and complements standard magnetic resonance imaging (MRI) to measure and track bowel movements.
This rate of motility is often affected by inflammation of the gastrointestinal tract – the more inflamed the bowel, the less it moves – and thus gives an idea of disease progression and response to treatment. With an initial focus on Crohn’s disease, GIQuant assists physicians in in-depth evaluation of images, providing data-driven insights to monitor therapeutic responses and enabling more informed clinical treatment decisions. This additional layer of objective data, collected in a non-invasive way, can help physicians more quickly identify ineffective treatments and speed up a patient’s course of treatment.
NIHR funding will support a retrospective study of historical MRI scans, focusing on training, and a promising component for more than 3,400 patients, in collaboration with clinicians and more than 10 UK hospitals, gathering real evidence to make changes to Crohn’s disease clinical management. Illness.
The study will also look at reducing the use of intravenous (IV) contrast dyes, which can cause serious side effects and could offer potential NHS savings of millions each year through a combination of efficacy and effectiveness.
Motilent CEO Alex Menis commented: “One of the first questions we are asked is, ‘Who else uses GIQuant?’ and thanks to this grant we have the opportunity to truly implement technology in many different types of hospitals and give the clinical community time and resources to see how GIQuant can fit their workflow.
“It’s certainly based on regulatory legal permits and a large number of published documents, but it can’t replace practical use.”
Gordon Moran, clinical associate professor at the University of Nottingham, commented: “This is a great work by Motilent. With a new approach to treating inflammatory bowel disease you need to have the right target that is accurate and affordable.
“This will allow us to better treat patients so that they can achieve a better quality of life. GIQuant defines all the necessary frameworks. “